Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

By F. Kabbinavar, J. Schulz, M. Mccleod, T. Patel, J. Hamm, J. Hecht, R. Mass, B. Perrou, B. Nelson, W. Novotny. Journal of Clinical Oncology, 2005

987 citations recorded by the source corpus.

Subfields: Hepatology, Oncology

View Paper: https://www.semanticscholar.org/paper/f77fc3efc8a87a8a94388859b6d2f7f6d0c498f6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. D. McDonald
2. P. Steeg

Citations in the corpus

• Tumor metastasis: mechanistic insights and clinical challenges (2006, background): “, and bevacizumab has shown activity in metastatic colorectal carcinoma in combination with cytotoxic agent”
• Mechanisms of adverse effects of anti-VEGF therapy for cancer (2007, background): “Proteinuria was found in 23% of 1132 patients in clinical trials of bevacizumab in various types of cancer and was more common in patients receiving bevacizumab plus chemotherapy than in patients on chemotherapy alone (Hurwitz et al, 2004; Kabbinavar et al, 2005).”